Appeal against bortezomib monotherapy for relapsed multiple myeloma
The Institute has received four appeals from Janssen-Cilag Ltd, UK Myeloma Forum, a joint appeal from Myeloma UK, Cancerbackup and Leukemia CARE and a joint appeal from British Society Haematology and Royal College of Pathologists against the Final Appraisal Determination and Guidance on this technology.
An appeal hearing was held on 8 February 2007. The Institute awaits the decision of the appeal panel.
The booking period for this appeal has now closed.
This page was last updated: 30 March 2010